Publications by authors named "Carlos Appiani"

Claim this Profile
T
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
Jianming He, Luke Schmerold, Rian Van Rampelbergh, Lugui Qiu, Ravi Potluri, Carlos Appiani

Adv Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.
Dolly A Parasrampuria, Jianming He, Liping Zhang, Bogdan Muresan, Peter Hu, Carlos Appiani

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children.
Gerhard Leitz, Peter Hu, Carlos Appiani, Qing Li, Essack Mitha

J Pediatr Gastroenterol Nutr· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.
Wangda Zhou, Dolly A Parasrampuria, Sepideh Nemat, Susumu Nakahara, Italo Poggesi, Carlos Appiani

J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani

Br J Haematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Tadeusz Robak, Jie Jin, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Carlos Appiani

Lancet Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis